PlainPatent
USPTO 2015–2025 USPTO PatentsView US Corporation

Element Biosciences, Inc.

USPTO PatentsView assignee record - 41 granted patents across 11 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR).

Explore the portfolio See the ranking
41
Total patents granted
11
CPC technology areas
25.2
Avg claims per patent
-
5-year grant velocity

The verdict

According to USPTO PatentsView, Element ranks #7,837 of 50,000 tracked US assignees by granted-patent volume, with 41 patents across 11 technology areas.

#7,837
of 50,000 US assignees by volume
Top 4%
by Innovation Score (59.6/100)
25.2
avg claims per patent

Portfolio overview

Element Biosciences, Inc. has been granted 41 US utility patents between 2020 and 2025, placing Element Biosciences, Inc. at #7,837 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 11 distinct Cooperative Patent Classification (CPC) subclasses, averaging 25.2 claims per patent with primary concentration in C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR). As a US Corporation, Element Biosciences, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Element sits between Concealfab, Inc. (41 patents, rank #7,833) and Fujifilm Toyama Chemical Co., Ltd. (41 patents, rank #7,841) - the closest US assignees by grant volume. The composite Innovation Score of 59.6/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Grant cadence records the difference between two grant-year windows. Historical data spans 2020 through 2025, with 41 total grants over that period. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The US Corporation classification provides context for the assignee record, not a conclusion about its business strategy.

Claim depth and technology breadth describe this aggregate record. Element Biosciences, Inc.'s 25.2 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 11 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.

Who files at Element's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Element holds 41 patents at rank #7,837, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Element

By rank, the assignees closest to #7,837 in granted patent volume.

Leaders in C12Q (Measuring OR Testing Processes Involving Enzymes)

Other assignees with the most granted patents in Element's primary technology class.

Element's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

60 Top 4% higher than 96% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). Below this entry. 50–60: 5,058 US assignees (10%). Below this entry. 60–70: 1,537 US assignees (3%). This entry sits in this band. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

2468101214 202020212022202320242025 9
USPTO utility patent grants by year · 2020–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table
Element Biosciences, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2020 3 7.3%
2021 5 12.2%
2022 12 29.3%
2023 3 7.3%
2024 9 22.0%
2025partial year 9 22.0%

Which technologies does Element Biosciences, Inc. patent most?

Top 11 of 11 technology areas

Grant record at a glance

Portfolio Volume 41 grants
CPC subclasses 11
Avg. claims / grant 25.2

Historical grant data only; it does not rate legal strength or current strategy.

Where it ranks

Overall rank by patents

#7,837

of 50,000 tracked assignees

Innovation Score

59.6 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

Where does Element Biosciences, Inc. rank among US patent assignees?
According to USPTO PatentsView (2015–2025 granted utility patents), Element Biosciences, Inc. ranks #7,837 of 50,000 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.
How many patents does Element Biosciences, Inc. hold?
Element Biosciences, Inc. holds 41 US utility patents granted between 2020 and 2025, spanning 11 technology areas.
What is Element Biosciences, Inc.'s Innovation Score?
Element Biosciences, Inc. has an Innovation Score of 59.6 out of 100 (top 4% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Element Biosciences, Inc. focus on?
Element Biosciences, Inc.'s top technology area is C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES) with 37 patents. Grants appear in 11 CPC subclasses total.
Is Element Biosciences, Inc.'s patent grant rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for Element Biosciences, Inc..
What does claim depth mean for Element Biosciences, Inc.'s patents?
Element Biosciences, Inc.'s patents average 25.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.
How is the Element Biosciences, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Element's 41 grants land it in the top 4% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Element ranks #7,837 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in C12Q - see who else leads that technology area. C12Q leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.